medigraphic.com

2019, Número 1

<< Anterior Siguiente >>

Rev Hematol Mex 2019; 20 (1)


Linfomas no Hodgkin de estirpe T

Pérez-Zúñiga JM, Aguilar-Andrade C, Álvarez-Vera JL, Augusto-Pacheco M, Báez-Islas PE, Bates-Martín RA, Cervantes-Sánchez I, Espitia-Ríos ME, Estrada-Domínguez P, Jiménez-Alvarado R, Fermín-Caminero DJ, García-Camacho AS, Gómez-Rosas P, Grimaldo-Gómez FA, Guzmán-Mera P, Herrera-Olivares W, Martínez-Ramírez MA, Medina-Meza C, Mena-Zepeda V, Montoya-Jiménez L, Morales-Adrián JJ, Morales-Hernández AE, Mujica-Martínez A, Palma-Moreno OG, Reyes-Brena G, Reynoso-Pérez AC, Salazar-Ramírez Ó, Hernández-Ruiz E, Paredes-Lozano EP, Alvarado-Ibarra M

Idioma: Español
Referencias bibliográficas: 60
Paginas: 28-48
Archivo PDF: 347.60 Kb.


RESUMEN

Uno de cada diez linfomas no Hodgkin corresponden a estirpe T, existen limitaciones en el diagnóstico y tratamiento óptimos de este grupo de pacientes. Es necesario contar con documentos de sus características clínicas, localización, sistemas de clasificación y tratamiento. Esta revisión realiza un concentrado de lo mencionado, con la finalidad de consensar la epidemiología, características morfológicas, los estudios, técnicas de evaluación y tipos de tratamiento a prescribir, para así ofrecer a este grupo de enfermos una evaluación y manejo sistematizado. Este documento incluye el linfoma no Hodgkin de las variedades: T/NK nasal, micosis fungoide, T periférico y linfoblástico. Al ser menor el número de pacientes y estudios con mayores limitaciones que ofrezcan evidencia sólida en este campo, por la mayor heterogeneidad de los linfomas no Hodgkin estirpe T, se pretende concentrar las diferentes posturas en distintos grupos, que permitan homogeneizar en el nuestro el abordaje diagnóstico y terapéutico que mejore los resultados obtenidos hasta el momento en tasas de respuesta y supervivencia. Por último, se propone incorporar en nuestro medio las herramientas de diagnóstico, tratamiento y evaluación que han permitido lograr resultados más esperanzadores en esta población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kanavaros P, Lescs MC, Brière J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993;81(10):2688-2695.

  2. Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol 1999;30(7):849-855.

  3. Li T, Hongyo T, Syaifudin M, et al. Mutations of the p53 gene in nasal NK/T-cell lymphoma. Lab Invest 2000;80(4):493- 499.

  4. Chan JKC, Ng NA, Lau WH, Lo STH. Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 1987;11(9):742. doi:10.1097/00000478- 198709000-00024.

  5. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996;87(4):1207-1210.

  6. Chan JK, Ng CS, Lau WH, Lo ST. Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 1987;11(6):418-429.

  7. Ferry JA, Sklar J, Zukerberg LR, Harris NL. Nasal lymphoma. A clinicopathologic study with immunophenotypic and genotypic analysis. Am J Surg Pathol 1991;15(3):268-279.

  8. Ho FC, Choy D, Loke SL, et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 1990;21(10):1041-1050.

  9. Yan Z, Huang HQ, Wang XX, et al. A TNM staging system for nasal NK/T-cell lymphoma. PLoS ONE 2015;10(6):1-15.

  10. Li YJ, Li ZM, Xia Y, et al. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLOS ONE 2013;8(5):e64158.

  11. Huang JJ, Zhu YJ, Xia Y, Zhao W, Lin TY, Jiang WQ, Huang HQ, Li ZM. A novel prognostic model for extranodal natural killer/T-cell lymphoma. Med Oncol 2012 Sep;29(3):2183- 90. doi: 10.1007/s12032-011-0030-x.

  12. Cai Q, Luo X, Liang Y, et al. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. Br J Cancer 2013;108:380-386.

  13. Cai Q, Luo X, Liang Y, et al. A new prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Blood 2013;122:1769.

  14. Seyoung S, Jung Y, Dok H, et al. A prognostic index for extranodal natural killer/T cell lymphoma after nonanthracycline- based treatment (PINK-B): Prognostic index of natural killer cell lymphoma (PINK) combined with serum beta-2 microglobulin. Blood 2016;128:1821.

  15. Jin-Hua L, Chong-Yang D, Li W, et al. The prognostic value of whole-body suvmax of nodal and extranodal lesions detected by 18F-FDG PET-CT in patients with extranodal NK/T-cell lymphoma. Blood 2015;126:3918.

  16. Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (Aspa- MetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117(6):1834-9.

  17. Motoko Y, Kensei T, Masahiko O, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG021. J Clin Oncol 2009;27:5594-5600.

  18. Seok J, Kihyun K, Byung S, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by vipd chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma Study. J Clin Oncol 2009;35:6027-6032.

  19. Jiang M, Zhang H, Jiang Y, et al. Etoposido 100 mg/m2sc IV. Días 2, 3 y 4. Phase 2 trial of “sandwich” L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer 2012;118(13):3294-301.

  20. Yan G, Hui-qiang H, Cai Q, et al. Efficacy and safety of pegaspargase with gemcitabine and oxaliplatin in patients with treatment-naïve, refractory extranodal natural killer/T-cell lymphoma: a single-centre experience. Blood 2013;122:642.

  21. Bi XW, Xia Y, Zhang WW, et al. Radiotherapy and PGEMOX/ GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol 2015;94(9):1525-33.

  22. Motoko Y, Yok-L, Won S, et al. Phase II Study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: The NK-Cell Tumor Study Group Study. J Clin Oncol 2011;4410-4416.

  23. Avilés A, Neri N, Fernández R, et al. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003;20:13-17.

  24. Crowley JJ, Nikko A, Varghese A, Hoppe RT, Kim YH. Mycosis fungoides in young patients: clinical characteristics and outcome. J Am Dermatol 1998;38(5 Pt 1):696-701.

  25. Quaglino P, Zaccagna A, Verrone A, Dardano F, Bernengo MG. Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical course. Dermatology (Basel) 1999;199(1):8-14.

  26. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010;116(19):3724- 3734. doi:10.1182/blood-2010-05-282632.

  27. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143(7):854-859. doi:10.1001/archderm.143.7.854.

  28. Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013;149(11):1295-1299. doi:10.1001/jamadermatol. 2013.5526.

  29. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population- based study of 3884 cases. Blood 2009;113(21):5064- 5073. doi:10.1182/blood-2008-10-184168.

  30. Fujita A, Hamada T, Iwatsuki K. Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008. J Dermatol 2011;38(6):524-530. doi:10.1111/j.1346- 8138.2010.01049.x.

  31. Van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005;23(17):3886- 3896. doi:10.1200/JCO.2005.11.353.

  32. Shin J, Monti S, Aires DJ, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007;110(8):3015- 3027. doi:10.1182/blood-2006-12-061507.

  33. Wong HK. Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma. Discov Med 2013;16(87):71-78.

  34. Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 1989;81(20):1560-1567.

  35. Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol 2011;64(2):423-431. doi:10.1016/j.jaad.2009.11.692.

  36. Li G, Vowels BR, Benoit BM, Rook AH, Lessin SR. Failure to detect human T-lymphotropic virus type-I proviral DNA in cell lines and tissues from patients with cutaneous T-cell lymphoma. J Invest Dermatol 1996;107(3):308-313.

  37. Wood GS, Salvekar A, Schaffer J, et al. Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma. J Invest Dermatol 1996;107(3):301-307.

  38. Muñoz-González H, Molina-Ruiz AM, Requena L. Clinicopathologic variants of mycosis fungoides. Actas Dermosifiliogr 2017;108(3):192-208. doi:10.1016/j. ad.2016.08.009.

  39. Foss FM, Girardi M. Mycosis fungoides and Sezary syndrome. Hematol Oncol Clin North Am 2017;31(2):297-315. doi:10.1016/j.hoc.2016.11.008.

  40. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53(6):1053- 1063.

  41. Belousova IE, Samtsov AV, Kazakov DV. A rare case of solitary hemorrhagic mycosis fungoides with angiocentric features. Am J Dermatopathol 2017;39(4):313-315. doi:10.1097/DAD.0000000000000759.

  42. Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009;33(12):1860- 1868. doi:10.1097/PAS.0b013e3181bf677d.

  43. Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 2012;119(7):1643-1649. doi:10.1182/blood-2011-08-376319.

  44. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009 Nov 12;114(20):4337-53. doi: 10.1182/blood-2009-07-202895. Epub 2009 Aug 20.

  45. Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. Blood 2016 Jun 23;127(25):3142-53.

  46. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29(18):2598-607.

  47. Trautinger, et al. Eur J Cancer 2017;77:57e74.

  48. Al Hothali GI. Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach. Int J Health Sci (Qassim) 2013;7(2):220-39.

  49. Bernt KM, Armstrong SA. Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol 2009;46(1):33-38. doi:10.1053/j.seminhematol. 2008.09.010.

  50. Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. Blood 1999;93(9):2760- 2770.

  51. Szczepański T, Pongers-Willemse MJ, Langerak AW, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999;93(12):4079-4085.

  52. Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American- British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999;111(4):467-476.

  53. Bernard A, Boumsell L, Reinherz EL, et al. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 1981;57(6):1105-1110.

  54. Gouttefangeas C, Bensussan A, Boumsell L. Study of the CD3-associated T-cell receptors reveals further differences between T-cell acute lymphoblastic lymphoma and leukemia. Blood 1990;75(4):931-934.

  55. Gutiérrez-García G, et al. Ann Oncol 2011;22:397-404.

  56. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN- 35). Clinical Cancer Research 2011;17(20):6428-6436. doi:10.1158/1078-0432.CCR-11-0488.

  57. Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: The BENTLY Trial. J Clin Oncol 2016;31(1):104-110. doi:10.1200/ JCO.2012.43.7285.

  58. O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol 2016;33(23):2492-2499. doi:10.1200/JCO.2014.59.2782.

  59. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab Vedotin (SGN-35) for relapsed CD30-positive lymphomas. http:// dxdoiorg/101056/NEJMoa1002965. 2010;363(19):1812- 1821. doi:10.1056/NEJMoa1002965.

  60. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103(8):2920- 2924. doi:10.1182/blood-2003-10-3389.




2020     |     www.medigraphic.com